Post Traumatic Stress Disorder Market Size

Global Post-Traumatic Stress Disorder Market Overview

Post-Traumatic Stress Disorder Market Size was valued at USD 17.61 Billion in 2023. The Global Post-Traumatic Stress Disorder industry is projected to grow from USD 18.47 Billion in 2024 to USD 27.11 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.43% during the forecast period (2024 - 2032).

Increase in the number of clinical trials pertaining to post-traumatic stress disorder treatment and rise in R&D activities for the introduction of novel therapies and drugs are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Post-Traumatic Stress Disorder Market Trends

• Increase cases of PTSD to boost market growth

The increase in the incidence of post-traumatic stress disorder is so great that 1 in 13 people will develop the disorder at some point in their lives. According to an NCBI article, 70% of adult Americans have experienced at least one traumatic event for, and 20% of them will develop PTSD as a result of such an event. The prevalence of this condition is higher in women than in men, as victims of sexual violence and rape are major sources of traumatic experiences. The prevalence in women is approximately 9.7% compared to approximately 3.6% in men. Additionally, the rise of natural and man-made disasters, such as the COVID-19 pandemic and the Russo-Ukrainian War, continue to drive this case.

Further, growing demand for better treatment options will lead to R&D innovations and the launch of new therapeutic options, creating lucrative opportunities for market growth during the forecast period. For instance, For instance, Otsuka Pharmaceutical Development Inc.’s Brexpiprazole and Zoloft Combination is in phase 3 investigation for PTSD. Furthermore, Jazz Pharmaceuticals’ JZP150, Aptinyx’s NYX-783, and Bionomics’ BNC210 are under phase 2 clinical investigation, and such factors are expected to drive growth in the market over the forecast period. However, side effects associated with treatment for post-traumatic stress disorder are to be expected restrain growth over the forecast period.

Increasing product launches and collaborations among major market players in the treatment of PTSD are expected to drive the growth of the post-traumatic stress disorder treatment market during the forecast period. For example, on March 30, 2022, pharmaceutical company Sun Pharmaceutical Industries Ltd. signed a patent licensing agreement with pharmaceutical company H. Lundbeck to market and distribute its own version of vortioxetine (an antidepressant) in India. This product is approved in over 80 countries including the US, Europe, Canada and Australia.

Post-Traumatic Stress Disorder Market Segment Insights

Post-Traumatic Stress Disorder Treatment Insights

The market segments of post-traumatic stress disorder, based on Treatment, includes Prazosin, Anti-anxiety Medications, Psychotherapy, Medications, and Others. The Anti-anxiety Medications segment held the majority share in 2021 in respect to the Post-Traumatic Stress Disorder market revenue. This is primarily owing to the increase in R&D activities for Anti-anxiety Medications drugs against post-traumatic stress disorder, rise in government initiatives for post-traumatic stress disorder treatment & management, and increase in healthcare expenditure in developing countries across the globe.

Additionally, according to a SANE Australia update from April 2022, 12% of Australian people experience post-traumatic stress disorder throughout the course of their lifetime, compared to 1-2% of adults annually. Furthermore, this demonstrates the therapy for post-traumatic stress disorder is in extremely high demand. However, the expansion of the industry is also being aided by the increase in clinical trials. For instance, the SIU School of Medicine began a clinical trial in June 2020 to examine the efficacy and safety of a medicine that is being investigated for post-traumatic stress disorder.

March 2022 With the aim of marketing and distributing its own brand of the antidepressant drug vortioxetine in India under the trade name Vortidiftm, Sun Pharma entered into an exclusive patent licencing deal with the Danish pharmaceutical company Lundbeck. An innovative antidepressant with multimodal activity, vortioxetine has been given the green light to treat Major Depressive Disorder (MDD) in adults.

Post-Traumatic Stress Disorder End-User Insights

The Post-Traumatic Stress Disorder market segmentation, based on End-User, includes ambulatory surgical centers, and hospitals & clinics. The hospital & clinics segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is due to the increase in the number of patients visiting in hospital for post-traumatic stress disorder treatment therapy. Hence, rising applications of hospitals & clinics for Post-Traumatic Stress Disorder positively impacts the market growth.

Figure 2 Post-Traumatic Stress Disorder Market, by End-User, 2021 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Post-Traumatic Stress Disorder Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Post-Traumatic Stress Disorder market accounted for USD 0.46 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the increasing burden of post-traumatic stress disorder, growth in research and development activities as well as the presence of strong and established market players across the region.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3  POST-TRAUMATIC STRESS DISORDER MARKET SHARE BY REGION 2021 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Post-Traumatic Stress Disorder market accounts for the second-largest market share due to the increased awareness about therapeutic availability and efficacy, and initiatives from government and non-government organizations to strengthen and develop healthcare infrastructure, as well as a favorable reimbursement system. Further, the Germany market of post-traumatic stress disorder held the largest market share, and the UK market of post-traumatic stress disorder was the fastest growing market in the European region

The Asia-Pacific Post-Traumatic Stress Disorder Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due rise in the geriatric population and the rise in the number of mental and sexual abuse among adults. Moreover, China market of post-traumatic stress disorder held the largest market share, and the India market of post-traumatic stress disorder was the fastest growing market in the Asia-Pacific region

Post-Traumatic Stress Disorder Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of post-traumatic stress disorder to grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Post-Traumatic Stress Disorder industry must offer effective drugs or medications to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the  Post-Traumatic Stress Disorder industry to benefit clients and expand the market sector is to develop and introduce drugs that helps in effective treatment. In recent years, Post-Traumatic Stress Disorder industry has provided medicine with some of the most significant benefits. The Post-Traumatic Stress Disorder market major player such as Mylan NV (US), Greenstone LLC (US), Bionomics (Australia), Tonix Pharmaceuticals Holding Corp. (US), Marinus Pharmaceuticals Inc. (US), Azevan Pharmaceuticals (US), Lundbeck A/S (Denmark), and others are working to expand the market demand by investing in research and development activities.

Bionomics Ltd operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a pipeline of novel therapeutic ion channel targeting drug candidates to improve the lives of patients suffering from central nervous system (CNS) disorders. Bionomics serves customers in Australia. In November 4, 2019, Bionomics limited, a  clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the BNC210 development program for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders..

Also, The goal of Tonix, a clinical-stage biopharmaceutical firm, is to find, acquire, licence, and develop therapies to treat, prevent, and lessen pain in humans. Tonix's product pipeline includes candidates for the central nervous system (CNS), uncommon diseases, immunology, and infectious diseases. Small molecules and biologics for the treatment of pain, neurologic, psychiatric, and addiction problems are included in Tonix's CNS portfolio. TNX-102 SL1 is a potential treatment for a group of individuals with Long COVID syndrome, and Tonix Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, reported in August 2022 that the first patient has been enrolled in the Phase 2 PREVAIL study of this drug. As a daily bedtime medication for Long COVID, fibromyalgia, PTSD, alcohol use disorder, and agitation in Alzheimer's disease, TNX-102 SL is currently undergoing clinical testing.

Key Companies in the market of post-traumatic stress disorder includes

• Mylan NV (US)


• Greenstone LLC (US)


• Bionomics (Australia)


• Tonix Pharmaceuticals Holding Corp. (US)


• Marinus Pharmaceuticals Inc. (US)


• Azevan Pharmaceuticals (US)


• Lundbeck A/S (Denmark)


• Eli Lily and Company (US)


• Pfizer (US)


• GlaxoSmithKline (UK)

Post-Traumatic Stress Disorder Industry Developments

May 2022 At Biomed Israel, Madrigal Mental Care debuted its nanotechnology for the management and avoidance of post-traumatic stress disorder.

In January 2022 For the purpose of treating veterans with post-traumatic stress disorder (PTSD) using psychoactive-assisted psychotherapy, Mydecine Innovations Group Inc. has partnered with Combat Stress and the King's College London.

Post-Traumatic Stress Disorder Market Segmentation

Post-Traumatic Stress Disorder Treatment Outlook

• Prazosin


• Anti-anxiety Medications


• Psychotherapy


• Medications


• Others

Post-Traumatic Stress Disorder End-Users Outlook

• Ambulatory Surgical Centers


• Hospitals and clinics

Post-Traumatic Stress Disorder Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America